Skip to main content
. Author manuscript; available in PMC: 2017 Jul 18.
Published in final edited form as: Sci Transl Med. 2017 Jan 18;9(373):eaag2196. doi: 10.1126/scitranslmed.aag2196

Fig. 3. Tumor-associated CTL imaging with [18F]FHBG.

Fig. 3

[18F]FHBG PET imaging was performed in a 66 year-old male (Patient 6) with a recurrent right frontoparietal glioblastoma before (A) and one week after (B) CTL infusions. Allogeneic CTLs and IL-2 were injected intratumorally (red arrows) as described in Materials and Methods. Tumor recurrence was monitored by T1-weighted (T1W) MRI (top panels). [18F]FHBG PET images were fused with MRI images (bottom panels), and 3D volumes of interest were drawn using a 50% [18F]FHBG SUVmax threshold, outlined in yellow. (C) Voxel-wise analysis of [18F]FHBG SUV in pre- and post-CTL infusion scans.